Haemonetics shares have fallen 7.2% over the last six months to $75.12, underperforming the S&P 500's 6.1% gain. The company's organic revenue growth averaged just 2.9% annually over the past two years, lagging the medical devices sector and signaling weak demand in its core business. With trailing 12-month revenue of $1.33 billion, Haemonetics lacks the scale to compete effectively in the resource-intensive healthcare industry. Its five-year average return on invested capital was 6.4%, well below the 20% or more generated by top healthcare firms. The stock now trades at 14.8 times forward earnings, but analysts see better opportunities elsewhere.
Haemonetics CorporationOrganic revenue growth averaged only 2.9% annually, signaling weak demand in core business.
NVIDIA Corporation
Palantir Technologies Inc.